OR WAIT null SECS
Biotechnology company, Polyplus-transfection, has started construction of a new facility in France to meet growth in the cell and gene therapy market.
Biotechnology company, Polyplus-transfection, has announced in a Jan. 27, 2021 press release that it has started construction of a new facility in France to meet growth in the cell and gene therapy market.
The Vectura facility will be 4000 m2 and will house the company’s head office. Several immediate priorities will be fulfilled for the company upon the completion of the new facility, including doubling of the company’s headcount. Additionally, the new facility will provide additional manufacturing capacity for ex-vivo and in-vivo therapy products.
“The gene and cell therapy market continues to grow at a high rate, with more late-stage clinical trials moving towards commercialization, additionally supported by an increase in earlier stage therapies moving into the clinic. As a supplier of critical strategic materials for the sector, Polyplus-transfection will continue to invest to increase its capabilities and support its global customer base,” said Mario Philips, CEO, Polyplus-transfection, in the press release.
According to the company, the facility is expected to be operational in the third quarter of 2021.